News

Investors in the round included OrbiMed, Pontifax Fund, RA Capital Management, EcoR1 Capital, Omega Funds, BVF Partners L.P., Boxer Capital, LLC, Adage Capital Management L.P., and Alexandria Venture

The Odyssey Outcomes trial, which met its primary endpoint, was held in nearly 19,000 patients who had a recent acute coronary syndrome (ACS) event, such as a heart

Tofacitinib is a Janus kinase (JAK) inhibitor, which is yet to secure approval for the treatment of UC. The FDA and the European Medicines Agency (EMA) are currently reviewing the

The Type II variation regulatory approval has been supported by data from a non-inferiority lung function study, which demonstrated that patients with adequately controlled asthma were able to

Enrolment is open to patients who participated in Phase 1 clinical trials of ezutromid but did not meet the entry criteria for the main PhaseOut DMD cohorts. Patients

The platform will be led by Evotec for which Sanofi will license more than ten of its infectious disease research and early-stage development portfolio. Evotec will run the

Lenvima is an orally available tyrosine kinase inhibitor discovered by Eisai. The partnership will jointly develop and commercialize Lenvima as monotherapy and in combination with Merck’s anti-PD-1 therapy

Other investors Oriza Seed Capital, Yipu Capital, AVICT Global Holdings, and existing investors WuXi AppTec Group, and Juno Therapeutics also took part in the funding round. JW Therapeutics

Under the terms of the agreement, Ligand will receive upfront license fees, and is eligible to receive clinical and regulatory milestone payments as well as sales-based milestone payments